November 2011
Dr Paul Donnelly has been awarded an ARC Linkage grant worth over $500,000, with Clarity Pharmaceuticals as an industry partner. Dr Donnelly is a Senior Lecturer of the School of Chemistry at the University of Melbourne and a member of the Bio21 Institute, whose vision is to “improve health and the environment through innovation in biotechnology, driven by multidisciplinary research and dynamic engagement with industry”. Dr Donnelly and his research group focus on the application of synthetic organic/inorganic chemistry to biology and materials science and are involved with the development of metal-based radiopharmaceuticals for imaging and therapy of cancer.
Dr Donnelly’s work with Clarity Pharmaceuticals will involve cutting-edge research into gallium and copper radiopharmaceuticals for cancer diagnosis and therapy. The project will run for 3 years, starting in 2012.
About ARC Linkage grants
Commercialisation Australia is a hands-on assistance program delivered by the Australian government. Their support is driven towards helping products or services with high potential to enter the market. For further information please visit: http://www.commercialisationaustralia.gov.au
About Dr Paul Donnelly
Dr Paul Donnelly and his research group focus on the application of synthetic organic/inorganic chemistry to biology and materials science. Their multidisciplinary research approach is focussed on the application of coordination chemistry to metal-based drugs and the study of metal ions in biological systems. In addition, they are interested in the role of metal ions in biology including the development of metal-based radiopharmaceuticals for imaging and therapy of cancer.
